This competitive grant program seeks to support independent medical education addressing the unmet medical need in High-Risk BCG Non-Muscle Invasive Bladder Cancer (NMIBC and corresponding safe and effective integration of PD(L)1 inhibitors with a focus on urology and medical oncology shared decision-making.

Eligibility

• Geographic Scope:  Europe is a priority region, although proposals with global reach are acceptable.
• The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
• Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
• Suppose the project involves multiple departments within an institution and/or between different institutions/organizations/associations. In that case, all institutions must have a relevant role, and the requesting organization must have a key role in the project.
• The applicant must be the project/program lead or an authorized designee of such individual (e.g., project/program lead’s grant coordinator).
• The project/program lead must be an employee or contractor of the requesting organization.
• The requesting organization must be legally able to receive award funding directly from Pfizer Inc.

Funding Range and Project Length: Individual projects requesting up to $50,000-$250,000 will be considered. A total of $250,000 will be available for funding multiple projects.

Submission deadline: October 14, 2025